Ultragenyx Pharma (RARE) PT Rises To $62 At Citi But Remains At Neutral Pending Higher Dose Data
Tweet Send to a Friend
Citi analyst, Yigal Nochomovitz, reiterated his Neutral rating on Ultragenyx Pharma (NASDAQ: RARE) and raised his price target to $62 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
